Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Roundup

This article was originally published in The Tan Sheet

Executive Summary

FDA warns eye supplement marketer; Kentucky age-restricts OTC DXM sales; FDA, EPA data-sharing pact; Colorado, Maine pass microbead laws; and more news in brief.

You may also be interested in...



FDA Guidance Stirs In Caffeine Restrictions For Supplements

"An inherent feature of the conditions of use for such products is that the consumer must separate out a very small, precise serving from a potentially lethal amount of product – a task that poses a significant or unreasonable risk of illness or injury," says FDA's Office of Dietary Supplement Programs. Only products containing pure caffeine that packaged in the ingredient in premeasured doses and bulk caffeine that is sufficiently diluted will be considered compliant.

Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs

The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel